Skip to main content
Log in

Diquafosol Ophthalmic Solution for Dry Eye Treatment

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

There has been rapid progress in our understanding of dry eye pathogenesis, as well as the development of improved diagnostic clinical tests. Various types of dry eye treatment drugs have been developed. This review summarizes the basic and clinical research carried out in the development of diquafosol for ophthalmic use.

Results

Diquafosol is a dinucleotide, purinoreceptor P2Y2 receptor agonist. Basic pharmacological studies have shown that it acts on P2Y2 receptors at the ocular surface, to promote tear and mucin secretion via elevated intracellular Ca2+ concentrations. Diquafosol also improves tear and mucin secretion in experimental dry eye models. Based on the results of laboratory experiments, the authors conducted a series of clinical studies in patients with dry eye disease. Diquafosol was effective in the treatment of dry eye disease at an optimal dose of 3% six times a day. In comparison to commercially available 0.1% sodium hyaluronate ophthalmic solution, 3% diquafosol ophthalmic solution showed non-inferiority in improving corneal fluorescein staining scores and superiority in improving keratoconjunctival Rose Bengal staining scores.

Conclusions

Diquafosol ophthalmic solution has a novel mechanism of action that is characterized by its stimulatory effects on tear and mucin secretion. This drug has the potential to be effective in patients with tear film instability and short break-up time type of dry eye, which are essential factors in dry eye pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lemp MA. Report of National Eye Institute/Industry Workshop on clinical trials in dry eyes. CLAO J. 1995;21:221–232.

    PubMed  CAS  Google Scholar 

  2. Shimazaki J. Dry Eye Research Group in Japan. Definition and criteria of dry eye. Ganka. 1995;37:765–770.

    Google Scholar 

  3. DEWS members. 2007 Report of the International Dry Eye Workshop (DEWS). Ocul Surf. 2007;5:65–204.

    Article  Google Scholar 

  4. Shimazaki J. Dry Eye Research Group in Japan. Definition and diagnosis of dry eye 2006. J Eye. 2007;24:181–184.

    Google Scholar 

  5. Fahmy AM, Hardten DR. Treating ocular surface disease: new agents in development. Clin Ophthalmol. 2011;5:465–472.

    PubMed  Google Scholar 

  6. Nichols KK, Yerxa B, Kellerman DJ. Diquafosol tetrasodium: A novel dry eye therapy. Expert Opin Invest Drugs. 2004;13:47–54.

    Article  CAS  Google Scholar 

  7. Cowlen MS, Zhang VZ, Warnock L, Moyer CF, Peterson WM, Yerxa BR. Localization of ocular P2Y2 receptor gene expression by in situ hybridization. Exp Eye Res. 2003;77:77–84.

    Article  PubMed  CAS  Google Scholar 

  8. Li Y, Kuang K, Yerxa B, Wen Q, Rosskothen H, Fischbarg J. Rabbit conjunctival epithelium transports fluid, and P2Y2 receptor agonists stimulate Cl and fluid secretion. Am J Physiol. 2001;281:C595–C602.

    CAS  Google Scholar 

  9. Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res. 1998;67:341–346.

    Article  PubMed  CAS  Google Scholar 

  10. Takaoka-Shichijo Y, Murakami T, Nakamura M. Stimulatory effect of diquafosol tetrasodium on tear fluid secretion in normal rabbits. J Eye. 2011;28:1029–1033.

    CAS  Google Scholar 

  11. Murakami T, Fujita H, Fujihara T, Nakamura M, Nakata K. Novel non-invasive sensitive determination of tear volume changes in cats. Ophthalmic Res. 2002;34:371–374.

    Article  PubMed  Google Scholar 

  12. Fujihara T, Murakami T, Fujita H, Nakamura M. Nakata K. Improvement of corneal barrier function by the P2Y2 agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001;42:96–100.

    PubMed  CAS  Google Scholar 

  13. Fujihara T, Murakami T, Nagano T, Nakamura M, Nakata K. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther. 2002;18:363–370.

    Article  PubMed  CAS  Google Scholar 

  14. Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net Cl transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res. 2004;36:89–93.

    Article  PubMed  CAS  Google Scholar 

  15. Takaoka-Shichijo Y, Shinomiya K, Katsuta O, Nakamura M. Stimulatory action of diquafosol tetrasodium on mucin-like glucoprotein secretion in rabbit conjunctival tissues. J Eye. 2011;28:543–548.

    CAS  Google Scholar 

  16. Takaoka-Shichijo Y, Sakamoto A, Nakamura M. Effect of diquafosol tetrasodium on MUC5AC secretion by rabbit conjunctival tissues. J Eye. 2011;28:261–265.

    CAS  Google Scholar 

  17. Takaoka-Shichijo Y, Nakamura M. Stimulatory effect of diquafosol tetrasodium on the expression of membrane-binding mucin genes in cultured human corneal epithelial cells. J Eye. 2011;28:425–429.

    CAS  Google Scholar 

  18. Nakamura M, Imanaka T. New treatment for dry eye: diquafosol tetrasodium. Jpn J Ocular Pharmacol. 2011;25:42–46.

    Google Scholar 

  19. Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K; Diquafosol Ophthalmic Solution Phase 2 Study Group. The efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012; Jun 25 [Epub ahead of print].

  20. Takamura E, Tsubota K, Watanabe H, Ohashi Y. A randomized, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. In press.

  21. Yamaguchi M, Tsubota K, Watanabe H, Ohashi Y. The safety and efficacy of long-term treatment with 3% diquafosol ophthalmic solution for dry eye. J Eye. 2012;29:527–535.

    Google Scholar 

  22. Nelson JD. In-office diagnostic tests for dry eye disease. In: Asbell PA, Lemp MA, eds. Dry Eye Disease: The Clinician’s Guide to Diagnosis and Treatment. New York: Thieme Medical Publishers; 2006:33–46.

    Google Scholar 

  23. Kaido M, Matsumoto Y, Shigeno Y, Ishida R. Dogru M. Corneal fluorescein staining correlates with visual function in dry eye patients. Invest Ophthalmol Vis Sci. 2011;52:9516–9522.

    Article  PubMed  Google Scholar 

  24. Watanabe H. Significance of mucin on the ocular surface. Cornea. 2002;21:S17–S22.

    Article  PubMed  Google Scholar 

  25. Dua HS, Kruse FE. Innovations in the treatment of dry eye disease: mucin stimulators and hormone replacement. In: Asbell PA, Lemp MA, eds. Dry Eye Disease: The Clinician’s Guide to Diagnosis and Treatment. New York: Thieme Medical Publishers; 2006:108–113.

    Google Scholar 

  26. Dogru M, Tsubota K. Pharmacotherapy of dry eye. Expert Opin Pharmacother. 2011;12:325–333.

    Article  PubMed  CAS  Google Scholar 

  27. Shimazaki J. Risk factors for dry eye syndrome. Ganka. 2011;53:1553–1557.

    Google Scholar 

  28. Sakamoto A, Takaoka-Shichijo Y, Yamashita N, Nakamura M. Combined effect of diquafosol tetrasodium and purified HA ophthalmic solutions on tear fluid volume in normal rabbits. J Eye. In press.

  29. Dota A, Nakamura M. Combined effect of diquafosol tetrasodium and HA ophthalmic solutions in rat dry eye model. J Eye. 2011;28:1477–1481.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Masatsugu Nakamura.

Additional information

To view enhanced content go to www.advancesintherapy.com

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakamura, M., Imanaka, T. & Sakamoto, A. Diquafosol Ophthalmic Solution for Dry Eye Treatment. Adv Therapy 29, 579–589 (2012). https://doi.org/10.1007/s12325-012-0033-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-012-0033-9

Keywords

Navigation